The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
出版年份 2022 全文链接
标题
The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
作者
关键词
-
出版物
Pharmaceuticals
Volume 15, Issue 3, Pages 286
出版商
MDPI AG
发表日期
2022-02-28
DOI
10.3390/ph15030286
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
- (2021) Yuxin Huang et al. Experimental and Therapeutic Medicine
- SGLT2 inhibitors and the risk of diabetic ketoacidosis: A systematic review and meta-analysis
- (2021) Michael Colacci et al. Canadian Journal of Diabetes
- Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
- (2021) Annamaria Mascolo et al. DRUG SAFETY
- Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
- (2021) Concetta Rafaniello et al. Pharmaceuticals
- Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists
- (2021) Tamara Y. Milder et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
- (2021) Annamaria Mascolo et al. PHARMACOLOGICAL RESEARCH
- Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
- (2021) Xiang Zhou et al. Frontiers in Pharmacology
- Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database
- (2020) Yukari Katsuhara et al. CLINICAL DRUG INVESTIGATION
- Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT ‐2 study): 52‐week results from a randomized controlled trial
- (2020) Chantal Mathieu et al. DIABETES OBESITY & METABOLISM
- Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
- (2020) Yumin Gao et al. AMERICAN HEART JOURNAL
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
- (2020) Antonios Douros et al. ANNALS OF INTERNAL MEDICINE
- Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
- (2020) Rosanna Ruggiero et al. Frontiers in Pharmacology
- Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
- (2020) Anne L. Peters et al. DIABETES CARE
- Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies
- (2020) Moshe Phillip et al. DIABETES OBESITY & METABOLISM
- PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
- (2020) Gabriella di Mauro et al. DRUG SAFETY
- The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
- (2019) Stuart J. McGurnaghan et al. DIABETOLOGIA
- Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists
- (2019) Orly Vardeny et al. JACC-Heart Failure
- Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy
- (2019) Cristina Scavone et al. Expert Opinion On Drug Safety
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
- (2019) Thomas Danne et al. DIABETES CARE
- Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
- (2019) Annamaria Mascolo et al. Frontiers in Pharmacology
- SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis ‐ the STOP DKA Protocol
- (2019) Ronald M Goldenberg et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin: A Review in Type 1 Diabetes
- (2019) Julia Paik et al. DRUGS
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
- (2018) Chantal Mathieu et al. DIABETES CARE
- Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?
- (2018) Maurizio Sessa et al. Expert Opinion On Drug Safety
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
- (2017) Kelly R. Burke et al. PHARMACOTHERAPY
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
- (2016) Ronald M. Goldenberg et al. CLINICAL THERAPEUTICS
- Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
- (2015) E. M. Vivian AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
- (2014) Greg L. Plosker DRUGS
- Dapagliflozin: Glucuretic action and beyond
- (2014) Pitchai Balakumar et al. PHARMACOLOGICAL RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now